Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Syndax Pharmaceuticals Q4 EPS $(0.62) Beats $(0.65) Estimate

Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 134.25 percent decrease over earnings of $1.81 per share
byBill Haddad
February 28, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 134.25 percent decrease over earnings of $1.81 per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Canopy Growth’s Big Step Toward Entry Into US Cannabis Market As DEA Rescheduling Looms

By Jelena Martinovic
April 19, 1:28 PM
Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) said that in connection with the creation of the company's non-voting and non-participating exchangeable shares, on Thursday, April 18, Greenstar Canada Investment Limited Partnership and CBG Holdings LLC, each a wholly-owned subsidiary of Constellation Brands Inc (NYSE: STZ) exchanged all 17,149,925 common shares in the capital of the company they collectively held for 17,149,925 exchangeable shares for no consideration. The CBG Group no longer holds any common shares of Canopy, as a result, the company said on Thursday. In connection with the termination of the investor rights agreement between CBG, Greenstar and Canopy Growth, the parties entered earlier and following the note exchange, Garth Hankinson, Judy Schmeling and James Sabia each provided notice to the company of his or her decision to resign from the board.

CGC